Ipilimumab: Attenuation of an inhibitory immune checkpoint improves survival in metastatic melanoma

Expert Review of Anticancer Therapy

Volumn 10, Issue 11, 2010, Pages 1697-1701

  Peggs, Karl S ^a   Quezada, Sergio A ^b,c  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

CTLA 4; cytotoxic T lymphocyte antigen 4; immunotherapy; ipilimumab; melanoma; monoclonal antibody; Phase III; vaccine

Indexed keywords

CANCER VACCINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GLYCOPROTEIN GP 100; IPILIMUMAB; PEPTIDE VACCINE; TICILIMUMAB;

ADVANCED CANCER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COLITIS; DIARRHEA; ENDOCRINE DISEASE; HUMAN; HYPOPITUITARISM; MELANOMA; METASTASIS; NOTE; OVERALL SURVIVAL; VITILIGO;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; MELANOMA; NEOPLASM METASTASIS; SKIN NEOPLASMS; SURVIVAL ANALYSIS;

EID: 78649242082     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.144     Document Type: Note

References (21)

1. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu. Rev. Immunol. 22, 329-360 (2004).
2. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10(9), 909-915 (2004).
3. Peggs KS, Quezada SA, Allison JP. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Immunol. Rev. 224(1), 141-165 (2008).
4. Peggs KS, Segal NH, Allison JP. Targeting immunosupportive cancer therapies: accentuate the positive, eliminate the negative. Cancer Cell 12(3), 192-199 (2007).
5. Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J. Exp. Med. 206(8), 1717-1725 (2009). • Demonstration that cytotoxic T-lymphocyte antigen-4 blockade with monoclonal antibodies exerts anti-tumor activity via both effector and regulatory T-cell compartments.
6. Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells. J. Clin. Invest. 116(7), 1935-1945 (2006). • Demonstration of the cellular basis for activity of combination therapy, illustrating the importance of the intratumor ratio of effector to regulatory T cells.
7. Peggs KS, Quezada SA, Allison JP. Cancer immunotherapy: co-stimulatory agonists and co-inhibitory antagonists. Clin. Exp. Immunol. 157(1), 9-19 (2009).
8. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010).
9. Carthon BC, Wolchok JD, Yuan J et al. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin. Cancer Res. 16(10), 2861-2871 (2010).
10. Marshall MA, Ribas A, Huang H. Evaluation of baseline serum C-reactive protein (CRP) and benefit from tremelimumab compared to chemotherapy in first-line melanoma. J. Clin. Oncol. 28 (Suppl. 15) (2010) (Abstract 2690).
11. Harlin H, Meng Y, Peterson AC et al. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res. 69(7), 3077-3085 (2009).
12. Hodi FS, Mihm MC, Soiffer RJ et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl Acad. Sci. USA 100(8), 4712-4717 (2003).
13. Attia P, Phan GQ, Maker AV et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J. Clin. Oncol. 23(25), 6043-6053 (2005).
14. Phan GQ, Yang JC, Sherry RM et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyteassociated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl Acad. Sci. USA 100(14), 8372-8377 (2003).
15. Eggermont AM. Therapeutic vaccines in solid tumours: can they be harmful? Eur. J. Cancer 45(12), 2087-2090 (2009).
16. Schwartzentruber D, Lawson D, Richards J et al. A Phase III multi-institutional randomized study of immunization with the gp100:209-217 (210M) peptide followed by high-dose IL-2 compared with high-dose IL-2 alone in patients with metastatic melanoma. J. Clin. Oncol. 27 (Suppl. 18) (2009) (Abstract CRA9011). • Demonstration that gp100 peptide vaccination is unlikely to have a detrimental impact on survival outcomes in patients with melanoma.
17. Ribas A, Hauschild A, Kefford R et al. Phase III, open-label, randomized, comparative study of tremelimumab (CP-675, 206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma. J. Clin. Oncol. 26 (Suppl.) (2008) (Abstract LBA9011).
18. van Elsas A, Sutmuller R P, Hurwitz AA et al. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J. Exp. Med. 194(4), 481-489 (2001).
19. Quezada SA, Peggs KS, Simpson TR, Shen Y, Littman DR, Allison JP. Limited tumor infiltration by activated T effector cells restricts the therapeutic activity of regulatory T cell depletion against established melanoma. J. Exp. Med. 205(9), 2125-2138 (2008).
20. Cohen AD, Schaer DA, Liu C et al. Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PLoS ONE 5(5), e10436 (2010).
21. Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl Acad. Sci. USA 107(9), 4275-4280 (2010).